Lyra Therapeutics Inc Share
Lyra Therapeutics Inc Share price
Key metrics
| Market capitalization | $17.07m |
| Enterprise Value | $-32.19m |
| PER (TTM) P/E ratio | negative |
| EV/FCF (TTM) EV/FCF | 0.44 |
| EV/Sales (TTM) EV/Sales | -19.16 |
| P/S ratio (TTM) P/S ratio | 10.16 |
| P/B ratio (TTM) P/B ratio | 0.22 |
| Sales growth (TTM) Sales growth | 28.74% |
| Turnover (TTM) Turnover | $1.68m |
Is Lyra Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,945 stocks worldwide.
Lyra Therapeutics Inc Share analysis
Analyst opinions
5 Analysts have issued a Lyra Therapeutics Inc forecast:
Analyst opinions
5 Analysts have issued a Lyra Therapeutics Inc forecast:
Financial data from Lyra Therapeutics Inc
| Mar '24 |
+/-
%
|
||
| Net profit | -22 -22 |
38%
38%
|
|
| Depreciation and amortization | 0.14 0.14 |
50%
50%
|
|
| Share compensation | 2.16 2.16 |
34%
34%
|
|
| Operating cash flow | -22 -22 |
43%
43%
|
|
| Investments | 2.15 2.15 |
4,200%
4,200%
|
|
| Dividend paid | - - |
-
|
|
| Free cash flow | -25 -25 |
56%
56%
|
|
Figures in millions USD.
Don't miss a thing! We will send you all news about the Lyra Therapeutics Inc share directly to your mailbox free of charge.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Lyra Therapeutics Inc Share News
Company profile
Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. Its product candidates include LYR-210 and LYR-220, which are bioresorbable polymeric matrices for the treatment of chronic rhinosinusitis. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was founded in 2005 and is headquartered in Watertown, Massachusetts.
| Head office | United States |
| CEO | Maria Palasis |
| Employees | 88 |
| Founded | 2005 |
| Website | www.lyratherapeutics.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
